[ad_1]
William Blair restated their outperform rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report published on Friday morning,RTT News reports. William Blair also issued estimates for Xenon Pharmaceuticals’ Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.03) EPS and Q4 2026 earnings at ($1.06) EPS.
XENE has been the topic of a number of other research reports. Deutsche Bank Aktiengesellschaft assumed coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $67.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Finally, HC Wainwright reissued a “buy” rating and set a $53.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $57.38.
Check Out Our Latest Report on Xenon Pharmaceuticals
Xenon Pharmaceuticals Price Performance
Xenon Pharmaceuticals stock opened at $37.02 on Friday. The stock has a market cap of $2.82 billion, a price-to-earnings ratio of -13.13 and a beta of 1.20. The firm has a 50-day moving average of $39.27 and a two-hundred day moving average of $40.33. Xenon Pharmaceuticals has a 1 year low of $33.27 and a 1 year high of $50.99.
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($0.89) by $0.05. Research analysts expect that Xenon Pharmaceuticals will post -3.1 earnings per share for the current year.
Insiders Place Their Bets
In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 22,468 shares of Xenon Pharmaceuticals stock in a transaction on Friday, January 24th. The shares were sold at an average price of $40.20, for a total value of $903,213.60. Following the transaction, the chief executive officer now directly owns 31,302 shares of the company’s stock, valued at approximately $1,258,340.40. The trade was a 41.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Sherry Aulin sold 18,709 shares of the company’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total value of $770,997.89. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 57,492 shares of company stock worth $2,334,969. 5.52% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Xenon Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the business. Blue Trust Inc. raised its position in shares of Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 641 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in Xenon Pharmaceuticals during the 4th quarter valued at approximately $63,000. Quarry LP purchased a new position in shares of Xenon Pharmaceuticals in the fourth quarter worth $78,000. Avior Wealth Management LLC acquired a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth $101,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Xenon Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 487 shares during the period. Institutional investors and hedge funds own 95.45% of the company’s stock.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Read More
Receive News & Ratings for Xenon Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
Source link